PMID- 29951978
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 9
IP  - 4
DP  - 2018 Aug
TI  - Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated 
      with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial.
PG  - 1605-1614
LID - 10.1007/s13300-018-0462-9 [doi]
AB  - INTRODUCTION: To investigate the relative contribution rates of basal 
      hyperglycemia (BHG) and postprandial hyperglycemia (PPHG) to overall 
      hyperglycemia in patients with type 2 diabetes mellitus (T2DM) treated with 
      insulin lispro mix 25 and 50 (LM25 and LM50) as evaluated by continuous glucose 
      monitoring (CGM). METHODS: Eighty-one T2DM patients treated with premixed human 
      insulin 70/30 (PHI70/30) were randomly divided into two groups and received a 
      crossover protocol. In the first 16-week stage, one group received LM25 twice 
      daily, the other group received LM50 twice daily. In the second 16-week stage, 
      the two groups exchanged therapeutic regimen. Glycosylated hemoglobin (HbA(1c)) 
      measurement and CGM were performed at enrollment and at the end of each treatment 
      stage. RESULTS: BHG's contribution rate increased with increasing HbA(1c) (from 
      34.5% to 60.8%). PPHG's contribution rates in the LM50 regimen were significantly 
      lower than those in LM25 and PHI70/30 regimens at HbA(1c) levels < 7.5%. Compared 
      with LM50, LM25 shows a significant difference in reducing HbA(1c) in the 
      subgroup with baseline HbA(1c) >/= 8.5% (DeltaHbA(1c) LM25 vs. LM50 - 0.6 +/- 0.1% vs. 
      0.3 +/- 0.1%, p < 0.05). CONCLUSIONS: For T2DM patients treated with premixed 
      insulin analogues, postprandial hyperglycemia played a major role in the subgroup 
      of patients with HbA(1c) < 8.5%, while fasting hyperglycemia became the major 
      contributor to overall hyperglycemia in the subgroup of patients with 
      HbA(1c) >/= 8.5%. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier 
      ChiCTR-TTRCC-12002516. FUNDING: Lilly Suzhou Pharmaceutical Co., Ltd. (Shanghai 
      Branch, China) and National Key Program of Clinical Science of China 
      (WBYZ2011-873).
FAU - Li, Wei
AU  - Li W
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Ping, Fan
AU  - Ping F
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Xu, Lingling
AU  - Xu L
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhang, Huabing
AU  - Zhang H
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Dong, Yaxiu
AU  - Dong Y
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Li, Hongmei
AU  - Li H
AD  - Department of Endocrinology, China Meitan General Hospital, Beijing, China.
FAU - Sun, Qi
AU  - Sun Q
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Li, Yuxiu
AU  - Li Y
AUID- ORCID: 0000-0001-7500-0855
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      and Family Planning Commission, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 
      liyx@pumch.cn.
LA  - eng
GR  - WBYZ2011-873/National Key Program of Clinical Science of China/
PT  - Journal Article
DEP - 20180627
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6064593
OTO - NOTNLM
OT  - Insulin lispro
OT  - PPHG's contribution rate
OT  - Premixed human insulin
OT  - Type 2 diabetes mellitus
EDAT- 2018/06/29 06:00
MHDA- 2018/06/29 06:01
PMCR- 2018/06/27
CRDT- 2018/06/29 06:00
PHST- 2018/05/12 00:00 [received]
PHST- 2018/06/29 06:00 [pubmed]
PHST- 2018/06/29 06:01 [medline]
PHST- 2018/06/29 06:00 [entrez]
PHST- 2018/06/27 00:00 [pmc-release]
AID - 10.1007/s13300-018-0462-9 [pii]
AID - 462 [pii]
AID - 10.1007/s13300-018-0462-9 [doi]
PST - ppublish
SO  - Diabetes Ther. 2018 Aug;9(4):1605-1614. doi: 10.1007/s13300-018-0462-9. Epub 2018 
      Jun 27.